Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

241.22 +1.81 (+0.76%)

Streaming Delayed Price Updated: 10:57 AM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 09, 2022

Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on...

Via Benzinga

6 Analysts Have This to Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗

December 08, 2022

These biotech players beat the bear market this year.

Via The Motley Fool

3 Fierce Stocks That Are Screaming Buys in December ↗

December 07, 2022

Here are three winners in the making.

Via The Motley Fool

Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy ↗

December 05, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers...

Via Benzinga

Is Axsome Therapeutics Stock a Buy Now? ↗

November 11, 2022

The company seems to be coming into its own.

Via The Motley Fool

Why Shares of Zymeworks Rose 12.18% on Monday ↗

October 31, 2022

The biotech stock's shares may have been pushed by a short squeeze.

Via The Motley Fool

Why Zymeworks Stock Is Soaring Today ↗

October 19, 2022

Investors applauded a major licensing deal with Jazz Pharmaceuticals.

Via The Motley Fool

Biotech Space Offers Reward In 2023 Despite Economic Risks ↗

November 30, 2022

Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for...

Via Talk Markets

Struggling Axsome Stock Could Bounce Back on Drug Trial Success

November 30, 2022

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

Via MarketBeat

Q3 Proves To Be Another Tough Quarter For Cannabis ↗

November 28, 2022

It’s been a tough year for cannabis investors and Q3 offered little relief.

Via Talk Markets

Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling ↗

November 28, 2022

The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Want to Double Your Money? Buying These Stocks Could be a Genius Move ↗

November 28, 2022

These stocks are undervalued considering their long-term growth potential.

Via The Motley Fool

Prediction: This Growth Stock Could Double in 2023 ↗

November 24, 2022

The next year should be a busy one for this drugmaker.

Via The Motley Fool

Three CBD Stocks to Dominate a Budding Industry

November 23, 2022

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

Via MarketBeat

Topics Cannabis

Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling ↗

November 21, 2022

Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent.

Via Benzinga

Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent ↗

November 21, 2022

Via Benzinga

Got $500? 3 Growth Stocks to Buy That Could Double Your Money ↗

November 20, 2022

Innovative products and services could keep these companies growing.

Via The Motley Fool

3 Top Cannabis Stocks to Buy in November ↗

November 20, 2022

These solid performers are managing to grow revenue in a difficult environment.

Via The Motley Fool

2 Dirt Cheap Growth Stocks to Buy and Hold for Years ↗

November 18, 2022

In the long run, these stocks could deliver great returns.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

November 10, 2022

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:

Via Benzinga

Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance ↗

November 10, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.

Via Benzinga

Why Axsome Therapeutics Stock Slipped Today ↗

November 07, 2022

Investors traded out of the company following the latest earnings release, but only to a modest degree.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for November ↗

November 04, 2022

Catalysts lie ahead for these promising stocks.

Via The Motley Fool

2 Marijuana Stocks That Are Set for a Comeback ↗

October 28, 2022

Don't overlook these top stocks when investing in the marijuana space.

Via The Motley Fool

Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval ↗

October 26, 2022

A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals...

Via Benzinga

Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline ↗

October 21, 2022

Via Benzinga

Why Is Zymeworks (ZYME) Stock Up Today? ↗

October 19, 2022

Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ).

Via InvestorPlace

Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal ↗

October 19, 2022

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

All News about Jazz Pharmaceuticals plc - Ordinary Shares

Starting at $3.75/week.

Subscribe Today